Loading patent…
AssigneeCancer Research Malaysia
InventorsSan Jiun CHAI, Sammuel Chee Yong FONG, Chai Phei GAN, Sathibalan PONNIAH, Vyomesh PATEL, Sok Ching CHEONG, Kue Peng LIM
Estimating the term…
The present invention relates to a peptide composition capable of binding with major histocompatibility complex class I molecules to induce an anti-cancer immune response in a subject. Particularly, the peptide composition comprises at least a Four-jointed Box 1 peptide and a Melanoma Antigen family D4b peptide. The present invention further relates to the use of a peptide composition and a peptide vaccine for inducing the anti-cancer immune response in the subject.
A peptide composition characterised in that the peptide composition comprises at least a Four-jointed Box 1 (FJX1) peptide and a Melanoma antigen family D4b (MAGED4b) peptide which binds with major histocompatibility complex (MHC) Class I molecules for inducing an anti-cancer immune response in a subject.
Use of an effective amount of a Four-jointed Box 1 (FJX1) peptide and a Melanoma antigen family D4b (MAGED4b) in the manufacture of a medicament for treating any one or a combination of head and neck squamous cell carcinoma (HNSCC), breast cancer, colon cancer, rectum cancer, lung cancer, or prostate cancer in a subject in need thereof, wherein the medicament is capable of binding with major histocompatibility complex (MHC) class I molecules to induce an anti-cancer immune response in the subject.
Dependencies are inferred from the claim text.